Primary care experience on Stimunex® gocce in children with recurrent respiratory infections: a real-world study during the COVID-19 pandemic era.
- 2022-05-01
- RCT · n = 160
- Allergologia et immunopathologia 50(3)
- Alessandro Giannattasio
- Elena Poggi
- Gianfranco Trapani
- Cosimo Muia
- Luisella Zanino
- Massimo Landi
- Giorgio Ciprandi
- PubMed: 35527651
- DOI: 10.15586/aei.v50i3.562
- High evidence
- Large Human Trial
- Clinical
children in the Active group experienced shorter RI duration during the treatment and follow-up phases (p˂0.001 for both)
- Effect
- Beneficial
- Effect size
- Small
- Significant
- Yes